EUROPE CANCER BIOMARKER MARKET FORECAST 2019-2027

EUROPE CANCER BIOMARKER MARKET FORECAST 2019-2027

  • January 2019 •
  • 75 pages •
  • Report ID: 5067720 •
  • Format: PDF
KEY FINDINGS
The Europe cancer biomarker market is poised to grow at a CAGR of 10.83% for the years 2019-2027. Technological progress in research and developmental activities has progressed the growth of the cancer biomarker market in Europe.

MARKET INSIGHTS
The European market has a huge opportunity to grow in personalized medication on account of the support generated for the biomarkers test, growing medical tourism and the rising number of cancer patients in the region.Also, the various market segments and sub-segments with respect to biomarkers, application, cancer type and profiling technology are proving to be quite profitable for the market growth during the forecast period.

However, the lack of acceptance of the cancer biomarker from the general populace, unfavorable compensation and the shortage of skilled personnel are some of the major challenges faced by the market in the region.

COMPETITIVE INSIGHTS
Some of the leading players in the market are Agendia N.V., Becton Dickinson and Company, Qiagen N.V., Diadexus Inc. (Acquired By Diazyme Laboratories), Aureon Biosciences, Inc., Agilent Technologies, Inc., Clarient, Inc. (Acquired By Neogenomics Laboratories), Astellas Pharma Inc., Beckman Coulter, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Roche Diagnostics Ltd., Illumina, Inc. and Celgene Corporation.

Companies mentioned
1. ABBOTT LABORATORIES
2. AGENDIA N.V.
3. AGILENT TECHNOLOGIES, INC.
4. AUREON BIOSCIENCES, INC
5. ASTELLAS PHARMA INC.
6. BECKMAN COULTER
7. BECTON DICKINSON AND COMPANY
8. BRISTOL-MYERS SQUIBB
9. CELGENE CORPORATION
10. CLARIENT, INC. (ACQUIRED BY NEOGENOMICS LABORATORIES)
11. DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
12. ILLUMINA, INC.
13. ROCHE DIAGNOSTICS LTD
14. SANOFI
15. QIAGEN N.V.